In the light of such emerging in vivo evidence, site-specific phosphorylations found in the present study may be evaluated in the clinical context as a read-out for ERBB3/ERBB4 activity and therapeutic modulation, or studied to gain insights into proliferative, survival or other biological mechanisms linked to cancer progression by these RTKs. The gene discussed is ERBB4; the disease is cancer.